854P Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN).
Saved in:
| Title: | 854P Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN). |
|---|---|
| Authors: | Patnaik, M.M.1 (AUTHOR), Sekeres, M.A.2 (AUTHOR), DeZern, A.3 (AUTHOR), Luger, S.4 (AUTHOR), Sproat, L.5 (AUTHOR), Bejar, R.6 (AUTHOR), Hobbs, G.7 (AUTHOR), Roboz, G.J.8 (AUTHOR), Leoni, M.9 (AUTHOR), Martell, B.9 (AUTHOR), Padron, E.10 (AUTHOR) |
| Source: | Annals of Oncology. 2021 Supplement 5, Vol. 32, pS783-S784. 2p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 152688495 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 854P Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Patnaik%2C+M%2EM%2E%22">Patnaik, M.M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sekeres%2C+M%2EA%2E%22">Sekeres, M.A.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22DeZern%2C+A%2E%22">DeZern, A.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Luger%2C+S%2E%22">Luger, S.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sproat%2C+L%2E%22">Sproat, L.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bejar%2C+R%2E%22">Bejar, R.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hobbs%2C+G%2E%22">Hobbs, G.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Roboz%2C+G%2EJ%2E%22">Roboz, G.J.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leoni%2C+M%2E%22">Leoni, M.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martell%2C+B%2E%22">Martell, B.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Padron%2C+E%2E%22">Padron, E.</searchLink><relatesTo>10</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2021 Supplement 5, Vol. 32, pS783-S784. 2p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=152688495 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2021.08.147 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 2 StartPage: S783 Titles: – TitleFull: 854P Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Patnaik, M.M. – PersonEntity: Name: NameFull: Sekeres, M.A. – PersonEntity: Name: NameFull: DeZern, A. – PersonEntity: Name: NameFull: Luger, S. – PersonEntity: Name: NameFull: Sproat, L. – PersonEntity: Name: NameFull: Bejar, R. – PersonEntity: Name: NameFull: Hobbs, G. – PersonEntity: Name: NameFull: Roboz, G.J. – PersonEntity: Name: NameFull: Leoni, M. – PersonEntity: Name: NameFull: Martell, B. – PersonEntity: Name: NameFull: Padron, E. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2021 Supplement 5 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 32 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
